The lengthy antibody drug discovery collaboration between Sanofi and Regeneron Pharmaceuticals Inc. has been one of the industry's most productive partnerships, but it's poised to wind down at the end of the year, with implications for Sanofi's internal R&D.
Sanofi President-Global R&D Elias Zerhouni said the time is right for the broad antibody collaboration to come to an end,...








